KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBITDA: 2010-2025

Historic EBITDA for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$31.7 million.

  • Nektar Therapeutics' EBITDA rose 7.78% to -$31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.1 million, marking a year-over-year increase of 35.91%. This contributed to the annual value of -$105.2 million for FY2024, which is 60.10% up from last year.
  • Per Nektar Therapeutics' latest filing, its EBITDA stood at -$31.7 million for Q3 2025, which was up 12.58% from -$36.2 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year EBITDA high stood at $14.3 million for Q4 2024, and its period low was -$152.8 million during Q2 2022.
  • Moreover, its 3-year median value for EBITDA was -$36.2 million (2025), whereas its average is -$43.8 million.
  • As far as peak fluctuations go, Nektar Therapeutics' EBITDA crashed by 41.82% in 2021, and later soared by 142.82% in 2024.
  • Nektar Therapeutics' EBITDA (Quarterly) stood at -$112.9 million in 2021, then soared by 53.53% to -$52.5 million in 2022, then soared by 36.13% to -$33.5 million in 2023, then spiked by 142.82% to $14.3 million in 2024, then rose by 7.78% to -$31.7 million in 2025.
  • Its last three reported values are -$31.7 million in Q3 2025, -$36.2 million for Q2 2025, and -$44.5 million during Q1 2025.